Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Sedatives and Hypnotics Drugs: Benzodiazepines01:19

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Gut Microbiome as a Promising Frontier in Alzheimer's Disease Therapy.

Current neuropharmacology·2026
Same author

Chronobiotic and cytoprotective activity of melatonin in the cardiovascular system. Doses matter.

Npj biological timing and sleep·2026
Same author

Loss of melatonin signaling increases the risk of T2DM caused by metabolic disorders.

Cell communication and signaling : CCS·2025
Same author

Editorial: Aging epigenome and longevity.

Frontiers in aging·2025
Same author

Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities.

Brain sciences·2025
Same author

Special Issue "Tryptophan in Nutrition and Health 3.0".

International journal of molecular sciences·2025

Related Experiment Video

Updated: Jul 6, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Melatonergic drugs in clinical practice.

Rüdiger Hardeland1, Burkhard Poeggeler, Venkataramanujan Srinivasan

  • 1Johann Friedrich Blumenbach Institute of Zoology and Anthropology, Universityof Göttingen, Göttingen, Germany. rhardel@gwdg.de

Arzneimittel-Forschung
|March 29, 2008
PubMed
Summary

Melatonin receptor agonists like ramelteon and agomelatine offer improved treatment for sleep disorders and depression. Ramelteon is effective for insomnia and circadian rhythm issues, while agomelatine treats depression by improving sleep and mood.

More Related Videos

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Related Experiment Videos

Last Updated: Jul 6, 2026

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster
05:59

High-Throughput Small Molecule Drug Screening For Age-Related Sleep Disorders Using Drosophila melanogaster

Published on: October 20, 2023

Polygraphic Recording Procedure for Measuring Sleep in Mice
08:45

Polygraphic Recording Procedure for Measuring Sleep in Mice

Published on: January 25, 2016

Area of Science:

  • Pharmacology and Neuroscience
  • Sleep Medicine
  • Psychiatry

Background:

  • Melatonin (CAS 73-31-4) regulates sleep-wake cycles and has hypnotic properties, benefiting circadian rhythm sleep disorders (CRSD) like DSPS, jet lag, and shift-work disorder.
  • Elderly insomniacs often have low melatonin levels; exogenous melatonin can help, offering advantages over benzodiazepines and z-drugs due to lack of hangover, withdrawal, or addiction.
  • Limited efficacy of melatonin for primary sleep disorders is linked to its short half-life and downstream regulatory mechanisms, necessitating longer-acting melatonin receptor agonists.

Purpose of the Study:

  • To review the therapeutic potential of novel melatonin receptor agonists, ramelteon and agomelatine, for sleep disturbances and depression.
  • To compare the efficacy and safety profiles of ramelteon and agomelatine with existing treatments for insomnia and depression.

Main Methods:

  • Review of clinical data and meta-analyses on melatonin, ramelteon (CAS 196597-26-9), and agomelatine (CAS 138112-76-2).
  • Analysis of receptor binding affinities (MT1, MT2, 5-HT2C) and pharmacokinetic properties (half-life).
  • Evaluation of treatment outcomes in patients with insomnia, CRSD, and major depressive disorders.

Main Results:

  • Ramelteon, a long-acting agonist with high affinity for MT1/MT2 receptors, effectively treats elderly insomniacs and CRSD patients without adverse effects.
  • Agomelatine, an MT1/MT2 agonist and 5-HT2C antagonist, improves sleep and depressive symptoms in major depressive and seasonal affective disorders, unlike other antidepressants.
  • Both ramelteon and agomelatine show promise, but long-term safety studies are required, considering metabolites, redox effects, and potential reproductive impacts.

Conclusions:

  • Ramelteon represents a significant advancement for treating insomnia and CRSD due to its prolonged action and favorable safety profile.
  • Agomelatine offers a unique therapeutic approach for depression by simultaneously addressing sleep disturbances and mood symptoms.
  • Further long-term safety evaluations are crucial for both ramelteon and agomelatine to fully establish their clinical utility and safety.